‍The pharmaceutical industry has made a significant bet on artificial intelligence. But a growing body of evidence suggests that for most organisations, those bets are not paying off and the reason has very little to do with the AI itself.

According to a 2026 LogiPharma survey of 100 European supply chain heads, 65% of pharma supply chain leaders say they have limited confidence in AI's ability to predict or mitigate disruption. This is not a technology failure. It is a data failure.

AI in pharma supply chains is only as good as the information it is fed. And right now, the information is fragmented, siloed, and often trapped in systems that were never designed to talk to each other.

The State of the Industry: Ambitious but Disconnected

The investment signals are unmistakable. More than 85% of biopharma executives surveyed by ZS Associates confirmed they would invest in data, AI, and digital tools to build supply chain resilience. AI adoption is highest in demand planning (59%), inventory optimisation (57%), and logistics orchestration (49%). The momentum is real.

But so is the gap between ambition and execution. Only 36% of organisations are using AI in anything beyond isolated or experimental cases. The pharma supply chain, as analysts at IDC put it plainly, is full of companies deploying "local siloed improvement solutions and fragmented fixes" rather than building towards integrated intelligence.

This is the fundamental contradiction at the heart of pharma's AI challenge: the industry is data-rich, but the data is not connected.

What "Fragmented Data" Actually Means in Practice

When supply chain professionals talk about fragmentation, it can sound abstract. It is not.

A typical pharmaceutical supply chain generates data from manufacturing execution systems (MES), enterprise resource planning (ERP) platforms, quality management systems (QMS), warehouse management systems (WMS), cold chain sensors, third-party logistics providers, contract manufacturers, and regulatory compliance databases. Each of these systems was built at a different time, by a different vendor, for a different purpose.

As TraceLink's analysis of the issue notes, critical data exists in silos, information is not fully digitalised, and metadata is frequently added after the fact rather than embedded natively. The result is that AI models are reasoning over an incomplete picture — and in pharma, an incomplete picture is not just an operational inconvenience. It is a patient safety risk.

The consequences are concrete. A temperature excursion in a cold chain shipment might go undetected because sensor data from a logistics partner sits in a separate system and is only reconciled during batch reporting. A supplier at risk of disruption might not trigger an alert because procurement data and geopolitical risk feeds are not integrated with the forecasting model. A drug shortage might build for weeks before it becomes visible, because hospital demand signals never reach the manufacturer's planning system in real time.

These are not hypothetical scenarios. They are the documented failure modes of pharma supply chains operating without end-to-end data integration.

Why AI Cannot Compensate for Missing Connections

There is a persistent belief in the industry that sufficiently powerful AI can bridge data gaps — that a good enough model will find a way to work with what it has. This belief is wrong, and the industry's own performance data confirms it.

AI systems do not measure reality. They interpret inputs. A demand forecasting model trained on distributor sell-in data will not capture stockpiling behaviour by hospital procurement teams. A cold chain monitoring tool that reports sensor averages across a warehouse does not confirm product stability — it confirms what one sensor, at one point, recorded at one interval. Everything outside that narrow context is assumed to be stable.

The pharmaceutical supply chain research is equally blunt: AI models rely on accurate, complete datasets. When those datasets come from manufacturing, logistics, distribution, and clinical systems in inconsistent formats, the model output is unreliable — and unreliable outputs erode the trust needed to act on AI recommendations at speed.

This is why, despite heavy investment, 42% of AI initiatives in pharmaceutical companies fail to meet ROI expectations. The technology is not the bottleneck. The data foundation is.

The Five Data Integration Gaps That Break Pharma AI

1. Manufacturing to Distribution Disconnection

Production yield data, batch release schedules, and quality information rarely flow in real time to logistics planning systems. This means distribution plans are built on assumptions about output rather than actual facts. Machine learning models that could align logistics planning to manufacturing realities simply cannot do so when the two data environments remain separate.

2. Supplier Risk Blindness

Supplier qualification data, audit histories, geopolitical risk signals, and real-time capacity indicators are typically managed across procurement databases, email threads, and spreadsheets. When AI-driven risk models cannot access this information systematically, supply disruptions arrive as surprises rather than as predicted and managed events.

3. Cold Chain Sensor Gaps

Cold chain failures are one of the most costly and preventable supply chain risks in pharma. Yet as a recent Pharmaceutical Commerce analysis identifies, the dominant model — sensor outputs reported to a monitoring dashboard creates end-to-end reporting, not end-to-end visibility. Cross-docking, last-mile handovers, and loading/unloading transitions frequently occur outside continuous sensor coverage. AI cannot flag what it cannot see.

4. Demand Signal Latency

Traditional forecasting relies on distributor orders and historical sales data. But the demand signals that actually matter hospital admission rates, prescriber behaviour, epidemic patterns, policy changes — exist in healthcare systems that are rarely connected to pharma supply chain platforms. When an AI forecasting engine for an oncology drug integrated hospital admission data and electronic medical records alongside historical sales, it achieved a 25–30% reduction in forecast error and eliminated 80% of critical stockouts. Without that integration, the model was working blind.

5. Regulatory and Serialisation Fragmentation

The US Drug Supply Chain Security Act (DSCSA) and EU Falsified Medicines Directive (FMD) both require end-to-end product traceability. But many organisations still manage serialisation data separately from their broader supply chain systems, meaning compliance data and operational data cannot reinforce each other. AI-powered traceability the ability to locate any product unit in real time, automate recall management, and authenticate product provenance depends entirely on serialisation data being live and connected.

What End-to-End Integration Enables

The contrast with integrated environments is striking.

When supply chain data flows continuously across manufacturing, procurement, logistics, and distribution — with a unified data layer that gives AI models consistent, contextualised, real-time inputs the performance step-change is significant. Organisations with integrated AI supply chain environments report 30% higher forecasting accuracy using machine learning relative to traditional methods. AI-driven inventory management systems have reduced manual data entry from 30 hours per week to 5 hours, freeing human expertise for higher-order decision-making.

Pfizer's deployment of intelligent automation across its temperature-controlled logistics — integrating sensor data, production output, and distribution systems — reduced errors, improved cold chain efficiency, and delivered measurable patient outcome improvements. This was not achieved by better algorithms alone. It was achieved by giving those algorithms coherent, connected data to work with.

The strategic value of integration extends beyond operational metrics. With agentic AI moving to the centre of supply chain strategy in 2026 — AI systems capable of detecting deviations, predicting consequences, and taking corrective action with minimal human intervention — the requirement for high-quality, real-time, end-to-end data is not a nice-to-have. It is the prerequisite for the entire capability.

Building the Data Foundation: Where to Start

Pharma organisations that are accelerating AI ROI are, as the evidence consistently shows, doing one thing differently: they are weaving systems together before scaling models.

The practical starting point is identifying where the critical breaks are in the data chain the handover points where information stops flowing. Cold chain transitions, contract manufacturer reporting cycles, and distributor sell-through data are frequently the weakest links. Addressing these first delivers immediate operational value while establishing the integration infrastructure that scales.

Digital twins are emerging as an important bridging technology here. By building a virtual model of the supply chain that continuously ingests data from physical operations, organisations create the unified data environment that AI requires while also enabling scenario modelling, disruption simulation, and adaptive response planning.

Cloud infrastructure and IoT connectivity are the enabling layer. Drug manufacturers investing in smart factory upgrades — IoT sensors for real-time monitoring, cloud computing for large data volumes, advanced robotics for execution are not just modernising production. They are creating the data fabric that turns isolated AI pilots into connected, scalable intelligence.

The Regulatory Imperative

There is a compliance dimension to this that is easy to overlook when framing data integration as purely an efficiency question.

Regulatory expectations in 2026 are intensifying around data integrity, traceability, and collaboration. The expectation is not simply that pharma organisations can produce batch records and audit trails on request. It is that supply chain data is accurate, traceable, and connected across the entire product lifecycle — from raw material origin to patient delivery.

Fragmented data environments that work in isolation may pass point-in-time compliance checks. They will not meet the emerging standard of continuous, AI-supported compliance monitoring that regulators are moving towards. End-to-end data integration is increasingly a regulatory requirement as much as an operational one.

The Strategic Conclusion

The pharmaceutical supply chain is at an inflection point. The industry has built a solid operational foundation and invested significantly in AI capability. But stability is now being tested by volatility, tightening regulation, geopolitical disruption, and rising expectations from health systems and patients alike.

The path from reactive to proactive supply chain management — from responding to shortages after the fact to predicting and preventing them — runs through data integration. Not better models. Not more compute. Data that is fully digitalised, continuously flowing, and connected across every node in the supply chain.

AI in pharma supply chains is not failing because the technology is immature. It is failing because the data environments it depends on were never designed for it. The organisations that close that gap first will not just outperform on efficiency metrics. They will be the ones that reliably get medicines to patients when and where they are needed.

That is, ultimately, what the investment is for.

VE3 works with pharmaceutical and life sciences organisations to build the data integration architecture and AI deployment frameworks that translate supply chain AI investment into measurable clinical and operational outcomes. To explore how end-to-end integration could transform your supply chain performance, get in touch.

‍